ATE406159T1 - Behandlung von hyperlipidämie - Google Patents

Behandlung von hyperlipidämie

Info

Publication number
ATE406159T1
ATE406159T1 AT02729013T AT02729013T ATE406159T1 AT E406159 T1 ATE406159 T1 AT E406159T1 AT 02729013 T AT02729013 T AT 02729013T AT 02729013 T AT02729013 T AT 02729013T AT E406159 T1 ATE406159 T1 AT E406159T1
Authority
AT
Austria
Prior art keywords
hyperlipidemia
treatment
rar
mammal
inverse agonist
Prior art date
Application number
AT02729013T
Other languages
English (en)
Inventor
Yang-Dar Yuan
Scott Thacher
Elliot Klein
Roshantha Chandraratna
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE406159T1 publication Critical patent/ATE406159T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Polarising Elements (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrane Compounds (AREA)
AT02729013T 2001-05-03 2002-04-26 Behandlung von hyperlipidämie ATE406159T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/848,159 US20020193403A1 (en) 2001-05-03 2001-05-03 Methods of treating hyperlipidemia

Publications (1)

Publication Number Publication Date
ATE406159T1 true ATE406159T1 (de) 2008-09-15

Family

ID=25302507

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02729013T ATE406159T1 (de) 2001-05-03 2002-04-26 Behandlung von hyperlipidämie

Country Status (7)

Country Link
US (3) US20020193403A1 (de)
EP (2) EP1392284B1 (de)
JP (1) JP2004532239A (de)
AT (1) ATE406159T1 (de)
CA (1) CA2445504A1 (de)
DE (1) DE60228567D1 (de)
WO (1) WO2002089781A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7105566B2 (en) * 2002-10-22 2006-09-12 Allergan, Inc. Methods of treatment during vascular procedures
DE602004019685D1 (de) * 2003-12-26 2009-04-09 Allergan Inc DISUBSTITUIERTE CHALCOGENOXIME MIT ANTAGONISTISCHER WIRKUNG AM RAR(Gamma)-RETINOIDREZEPTOR
US7476673B2 (en) * 2003-12-30 2009-01-13 Allergan, Inc. Disubstituted chalcone oximes as selective agonists of RARγ retinoid receptors
WO2005093426A2 (en) * 2004-03-26 2005-10-06 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with retinoic acid receptor alpha (rara)
PT1937244T (pt) 2005-09-30 2018-11-07 Io Therapeutics Llc Tratamento do cancro com agonistas específicos de rxr
CA2651487A1 (en) * 2006-05-16 2007-11-29 Vitae Pharmaceuticals, Inc. Methods for treating chemotherapy and radiation therapy side effects
CN102015606B (zh) 2007-06-08 2015-02-04 满康德股份有限公司 IRE-1α抑制剂
MX352727B (es) 2011-12-13 2017-12-06 Dartmouth College Tratamiento de trastorno autoinmune al usar agonistas de rxr.
US20140094512A1 (en) * 2012-10-02 2014-04-03 Nikolas Gunkel Method of modulating the degree of adipose tissue deposited intramuscularly
DK3013813T3 (da) 2013-06-27 2019-06-03 Pfizer Heteroaromatiske forbindelser og anvendelse deraf som dopamin-d1-ligander
US11191755B2 (en) 2014-01-17 2021-12-07 Cornell University Compositions and methods for providing cardioprotective effects
US10092535B2 (en) 2015-10-31 2018-10-09 Io Therapeutics, Inc. Treatment of nervous system disorders using combinations of RXR agonists and thyroid hormones
WO2017151833A1 (en) * 2016-03-02 2017-09-08 Smith & Nephew, Inc. Soft tissue repair instruments and method
KR102549273B1 (ko) 2016-03-10 2023-06-28 아이오 테라퓨틱스, 인크. Rxr 작용제 및 갑상선 호르몬의 조합을 사용한 자가면역 질환의 치료
AU2016396659B2 (en) 2016-03-10 2019-02-14 Io Therapeutics, Inc. Treatment of muscular disorders with combinations of RXR agonists and thyroid hormones
US11517549B2 (en) 2017-09-20 2022-12-06 Io Therapeutics, Inc. Treatment of disease with esters of selective RXR agonists
EP3806839A4 (de) * 2018-06-14 2022-03-30 Cornell University Cornell Center For Technology, Enterprise & Commercialization ("CCTEC") Zusammensetzungen und verfahren zur bereitstellung von kardioprotektiven effekten
US10966950B2 (en) 2019-06-11 2021-04-06 Io Therapeutics, Inc. Use of an RXR agonist in treating HER2+ cancers
JP2023509372A (ja) * 2019-12-19 2023-03-08 オルファゲン ファーマシューティカルズ，インク． 炎症性疾患および男性避妊用ｒａｒアルファ化合物
WO2023108015A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist in treating drug resistant her2+ cancers
WO2023108012A1 (en) 2021-12-07 2023-06-15 Io Therapeutics, Inc. Use of an rxr agonist and taxanes in treating her2+ cancers

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5962731A (en) * 1992-04-22 1999-10-05 Ligand Pharmaceuticals Incorporated Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5780676A (en) * 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
US5691196A (en) * 1992-12-31 1997-11-25 American Cyanamid Company Recombinant nucleic acid containing a response element
EP0638071B1 (de) 1992-12-28 1997-04-09 Eisai Co., Ltd. Heterocyclische carbonsäure-derivate, die an rar rezeptoren binden können
US5739135A (en) * 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US6218128B1 (en) 1997-09-12 2001-04-17 Allergan Sales, Inc. Methods of identifying compounds having nuclear receptor negative hormone and/or antagonist activities
US5776699A (en) 1995-09-01 1998-07-07 Allergan, Inc. Method of identifying negative hormone and/or antagonist activities
US5958954A (en) * 1995-09-01 1999-09-28 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5877207A (en) 1996-03-11 1999-03-02 Allergan Sales, Inc. Synthesis and use of retinoid compounds having negative hormone and/or antagonist activities
US5728846A (en) 1996-12-12 1998-03-17 Allergan Benzo 1,2-g!-chrom-3-ene and benzo 1,2-g!-thiochrom-3-ene derivatives
US6037488A (en) 1997-04-19 2000-03-14 Allergan Sales, Inc. Trisubstituted phenyl derivatives having retinoid agonist, antagonist or inverse agonist type biological activity
US5919970A (en) 1997-04-24 1999-07-06 Allergan Sales, Inc. Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity
US6004928A (en) * 1997-05-13 1999-12-21 Biomeasure, Incorporated Method of treating hyperlipidemia
US5998654A (en) * 1997-07-25 1999-12-07 Ligand Pharmaceuticals Incorporated Retinoic acid receptor antagonist compounds and methods
US6107346A (en) * 1997-08-11 2000-08-22 Eli Lilly And Company Methods for treating hyperlipidemia
ATE289507T1 (de) * 1998-10-08 2005-03-15 Allergan Inc Rar-antagonisten zur verhütung für männer
US6093838A (en) * 1999-08-16 2000-07-25 Allergan Sales, Inc. Amines substituted with a dihydro-benzofuranyl or with a dihydro-isobenzofuranyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity
US11686053B2 (en) 2018-04-13 2023-06-27 Gomaco Corporation Three-dimensional bridge deck finisher

Also Published As

Publication number Publication date
US20080214652A1 (en) 2008-09-04
JP2004532239A (ja) 2004-10-21
EP1920771A2 (de) 2008-05-14
EP1392284A2 (de) 2004-03-03
CA2445504A1 (en) 2002-11-14
US20020193403A1 (en) 2002-12-19
EP1392284B1 (de) 2008-08-27
WO2002089781A2 (en) 2002-11-14
WO2002089781A3 (en) 2003-03-27
DE60228567D1 (de) 2008-10-09
EP1920771A3 (de) 2008-07-23
US20050171151A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
DE60228567D1 (de) Behandlung von hyperlipidämie
DE60133029D1 (de) Mittel zur prävention oder behandlung von psoriasi
DE60114808D1 (de) Oberflächenbehandlung von medizinischer vorrichtung
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
DE60120276D1 (de) Laserbehandlungsgerät
DE60105229D1 (de) Laserbehandlungsgerät
DE60138597D1 (de) Lumineszente Vorrichtung und dafür verwendete Metallkoordinationsverbindung
ATE426373T1 (de) Apparat zur behandlung von zahnen
NO20040635L (no) Forbedret shuntinnretning og fremgangsmate for behandling av glaukom
DE60235083D1 (de) Substituierte tetracyclin-verbindungen zur behandlung von malaria
DE50214540D1 (de) Stanz bei der behandlung von wunden
DE60204286D1 (de) Implantierbare vorrichtung
DE60234760D1 (de) Phenylindole zur behandlung von hiv
NO20001870D0 (no) Ny fremgangsmõte for behandling
DE60204951D1 (de) Ccr5 antagonisten verwendbar für die behandlung von aids
DE60100737D1 (de) Laserbehandlungsgerät
DE60136477D1 (de) Retinoide zur behandlung von emphysem
DE60204466D1 (de) Integrinhemmer zur behandlung von augenkrankheiten
ATE366569T1 (de) Verwendung von cox-2 inhibitoren als immunostimulantien zur behandlung von hiv oder aids
NO20025405D0 (no) Modulatorer for TNF-alfa-signalisering
DE60333205D1 (de) Histaminika zur behandlung von allergischer rhinitis
DE60033020D1 (de) Gerät zur behandlung von zahnkaries
DE50105735D1 (de) Chlorzoxazon zur behandlung von psoriasis
DE60224650D1 (de) Vorrichtung zur behandlung von vorhof-fibrillation
DE60200302D1 (de) Laseraugenbehandlungseinrichtung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties